Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Regulatory Sunset and Review Act

This article was originally published in The Tan Sheet

Executive Summary

Regulatory Sunset and Review Act: House Government Reform and Oversight Committee expects to consider HR 994 in early June. The Subcommittee on National Economic Growth, Natural Resources & Regulatory Affairs adopted the measure without amendment on May 18. Subcommittee Chairman David McIntosh (R-Ind.) describes the bill as "the next wave in regulatory reform" because it applies to existing regulations rather than new rules. Introduced by Reps. John Mica (R-Fla.) and Jim Chapman (D-Tex.), the bill would require agencies to review existing regs every seven years by applying risk assessment and cost-benefit standards. Rules would either remain in effect, or be modified, consolidated, or terminated. An identical measure was introduced in the Senate (S 511) by Sens. Pete Domenici (R-N.M.) and Spencer Abraham (R-Mich.) on March 7. Parts of the sunset bill are incorporated into pending Senate regulatory reform bills...

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts